Mitozolomide

Mitozolomide
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	85622-95-3
PubChem	71766
DrugBank
ChemSpider	64805
KEGG

Mitozolomide (INN) is an antineoplastic. It is an imidazotetrazine derivative.

Development of mitozolomide was discontinued during Phase II clinical trials after it was found to cause severe and unpredictable bone marrow suppression.<ref>,

 Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide, 
 Cancer Gene Ther, 
 
 Vol. 7(Issue: 2),
 pp. 233–9,
 DOI: 10.1038/sj.cgt.7700120,
 PMID: 10770631,
 
 
 Full text,</ref> Temozolomide, which has been in clinical use since 1999, is a less toxic analogue of mitozolomide.<ref>, 
 Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856), 
 Br J Cancer, 
 
 Vol. 65(Issue: 2),
 pp. 287–91,
 DOI: 10.1038/bjc.1992.57,
 PMID: 1739631,
 PMC: 1977719,</ref>

References

<references/>

• 
  Mitozolomide